Cardiac 123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan.

@article{Nakajima2015Cardiac1I,
  title={Cardiac 123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan.},
  author={Kenichi Nakajima and Tomoaki Nakata},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2015},
  volume={56 Suppl 4},
  pages={11S-19S}
}
Cardiac neuroimaging with (123)I-metaiodobenzylguanidine ((123)I-MIBG) has been officially used in clinical practice in Japan since 1992. The nuclear cardiology guidelines of the Japanese Circulation Society, revised in 2010, recommended cardiac (123)I-MIBG imaging for the management of heart failure (HF) patients, particularly for the assessment of HF… CONTINUE READING